Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, ...

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that the first patient has ...

Eli Lilly said on Tuesday its drug, Jaypirca, was more effective in a head-to-head study against AbbVie's Imbruvica when ...

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

The importance of a homegrown biomanufacturing workforce to North Carolina’s swiftly growing life sciences industry was a consistent theme during a recent press tour of the state attended by Fierce | ...

Wake Tech is excited to launch a distinctive apprenticeship program in partnership with life sciences leaders CSL Seqirus, ...

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...